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Accepted 14 May 2018; Published online 21 May 2018AbstractObjective: To synthesize the measurement properties of six health-related quality of life instruments (Short Form 36 [SF-36], Short
Form 12 [SF-12], EuroQol 5D-3L [EQ-5D-3L], EuroQol 5D-5L [EQ-5D-5L], Nottingham Health Profile (NHP), and Patient-Reported
Outcome Measurement Information System Global Health [PROMIS-GH-10]) in patients with low back pain (LBP).
Study Design and Setting: Six electronic databases (MEDLINE, EMBASE, CINAHL, PsycINFO, SportDiscus, and Google
Scholar) were searched (July 2017). Studies assessing any measurement property in nonspecific LBP patients were included. Two re-
viewers independently screened the articles and assessed the risk of bias (COSMIN checklist). Consensus-based criteria were used to
rate measurement properties results as sufficient, insufficient, or inconsistent; a modified GRADE approach was adopted for evidence
synthesis.
Results: High quality evidence was found for insufficient construct validity of SF-36 summary scores, and EQ-5D-3L utility and visual
analogue scale scores. Moderate evidence was found for sufficient construct validity of SF-12 physical summary score and inconsistent
responsiveness of EQ-5D-3L utility score. Very low quality evidence was found on each instrument’s content validity; very low to low
evidence underpinned the other assessed measurement properties. EQ-5D-5L, NHP and PROMIS Global Health-10 were not evaluated
in LBP patients.
Conclusion: Documentation of the measurement properties of health-related quality of life instruments in LBP is incomplete. Future
clinimetric studies should prioritize content validity.  2018 Elsevier Inc. All rights reserved.
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Low back pain (LBP) represents one of the most burden-
some and costly health conditions [1,2]. This condition has
important impacts on the patients’ health-related quality of
life (HRQoL) [3,4]. HRQoL (defined as ‘‘physical, psycho-
logical, and social domains of health, seen as distinct areas
that are influenced by a person’s experiences, beliefs, ex-
pectations, and perceptions’’) was also selected by an inter-
disciplinary group of stakeholders as a core outcome
domain for clinical trials in LBP [5]. However, it is unclear
which measurement instrument is best to measure this
domain.
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Key findings
 High quality evidence indicates that the construct
validity of the summary scores of the SF-36 and
of the utility and visual analogue scores of the
EQ-5D-3L is inadequate in patients with low back
pain (LBP).
 The quality of evidence on the content validity of
six instruments widely used to measure HRQoL
(i.e., SF-36, SF-12, EQ-5D-3L, EQ-5D-5L, NHP,
PROMIS Global Health-10) is very low in patients
with LBP.
What this adds to what is known?
 The measurement properties of HRQoL instru-
ments have been only marginally investigated in
patients with LBP.
 Caution should be used in assuming the validity of
the SF-36 and EQ-5D-3L scores in patients with
LBP, as there is high quality evidence suggesting
that correlations of these scores with other instru-
ments are not as expected.
What is the implication and what should change
now?
 More research on the measurement properties of
HRQoL instruments is needed in patients with
LBP, and priority should be given to head-to-
head comparison studies focusing on content
validity.
 Future head-to-head comparisons should also
assess structural validity, reliability, construct val-
idity and responsiveness, and they should also
include other recently developed instruments
(e.g., LBP Core Set Self-Report Checklist, Muscu-
loskeletal Health Questionnaire).The selection of an instrument should be based on its
measurement properties and feasibility in the target popula-
tion [6,7]. Previous recommendations on HRQoL measure-
ment in LBP have advocated the use of the Short Form 36
(SF-36), the Short Form 12 (SF-12) and/or the EuroQol 5D
(EQ-5D) [8e12]. The SF-36 is most frequently used to
measure HRQoL in LBP clinical trials, followed by the
Nottingham Health Profile (NHP), the SF-12, the Sickness
Impact Profile, and the EQ-5D [13]. The measurement
properties of these instruments have been investigated in
the general population and in various clinical samples
[14]. However, it remains unclear how valid, reliable, and
responsive these instruments are in patients with LBP.Three reviews have attempted to summarize the mea-
surement properties of HRQoL instruments in patients with
LBP [15e17]. Two were narrative reviews [16,17], two
focused on utility scores [15,17], and all had significant
and important methodological weaknesses, such as failure
to account for risk of bias in the evidence synthesis
[18,19]. The Consensus-based Standards for the selection
of health Measurement Instruments (COSMIN) initiative
has developed tools to guide systematic reviews on mea-
surement properties of patient-reported outcome measures
[20]; these include a taxonomy defining each measurement
property [21], a search filter to identify studies on measure-
ment properties [22], a risk of bias assessment checklist
[23], and evidence synthesis methods [24,25].
An international consortium developing a core outcome
measurement set for LBP clinical trials selected five instru-
ments as potential core outcome measurement instruments
for HRQoL in LBP [26]. Four of these instruments (SF-36,
SF-12, NHP and EQ-5D) were also among the five most
frequently used in LBP trials; the Sickness Impact Profile
was not selected because its length (136 items) rendered
it unfeasible for inclusion in a core set [26]. Although it
has not been broadly used, the 10-item Patient-Reported
Outcome Measurement Information System (PROMIS)
Global Health short form (PROMIS-GH-10) [27] was also
chosen because it demonstrated face validity similar to the
other instruments [26] and because it was recommended by
another recent core set initiative [28].
This systematic review summarizes the evidence on the
measurement properties of SF-36, SF-12, EQ-5D, NHP, and
PROMIS-GH-10 in patients with LBP. The results of this re-
view informed a Delphi survey to reach consensus on which
instrument(s) to recommend for core outcome measurement
of HRQoL in patients with LBP [26]. The original version
of the EQ-5D includes three response options for each item
(EQ-5D-3L) [29], and it has probably been the most used in
LBP; however, because a version with five response options
(EQ-5D-5L) was more recently developed [30], this newer
EQ-5D version was also assessed in this review.2. Methods
Conduct and report of this systematic review follows the
COSMIN guidance [24] and the Preferred Reporting Items
for Systematic Reviews and meta-Analysis statement [31].
The protocol was registered a priori in PROSPERO (https://
www.crd.york.ac.uk/prospero/), number CRD42015020021.2.1. Measurement instruments
2.1.1. Short Form 36
The SF-36 consists of 36 items measuring HRQoL sub-
divided in eight domains (Table 1). The number of response
options varies from three (physical functioning subscale) to
six (vitality and mental health subscales); originally, 0-100
25A. Chiarotto et al. / Journal of Clinical Epidemiology 102 (2018) 23e37scores were calculated for each domain, with higher scores
indicating better health [32], but currently, these are usually
expressed as t-scores. Two summary scores can be calcu-
lated: the physical component summary (PCS) and the
mental component summary (MCS); these are calculated
by summing factor-weighted scores across the eight sub-
scales. For the PCS, highest weights are given to the phys-
ical functioning, role physical, bodily pain and general
health scales; for the MCS, vitality, social functioning, role
emotional, and mental health scales give higher weights.
Factor weights are available from generic samples from
various countries [14].
2.1.2. Short Form 12
The SF-12 was developed by selecting 12 items of the SF-
36 to have a short HRQoL questionnaire (Table 1) [33]. It
measures the same eight domains of the SF-36 and enables
calculation of PCS and MCS summary scores. Similar to
the SF-36, the SF-12 can also be obtained online [14].
2.1.3. 3-Level EuroQoL 5D
The EQ-5D-3L was developed as a HRQoL measure to be
used in large-scale surveys and generate cross-national com-
parisons of health state valuations (Table 1) [29]. The first part
of the instrument consists of five items measuring mobility,
self-care, usual activities, pain/discomfort, and anxiety/
depression with three response options each; these response
options provide a profile (e.g., 21332) that is transformed into
a utility score based on values from the general population
[34]. The second part consists of a 0-100 vertical visual
analogue scale (VAS) that scores self-rated health from ‘‘best
imaginable health state’’ to ‘‘worst imaginable health state’’.
2.1.4. 5-Level EuroQol 5D
The utility part of the EQ-5D-3L was revised to improve
the responsiveness and ceiling effects, by increasing the
number of response options from three to five [30].
2.1.5. Nottingham Health Profile
The NHP was developed to capture perceived health sta-
tus in the population (Table 1). It consists of 45 items with
yes/no response options [35]. Thirty-eight items covering
six domains are included in the first part that provides 0-
100 scores for each domain; seven items covering seven
different domains are included in the second part [14].
2.1.6. PROMIS global health short form
The PROMIS-GH-10 was developed to assess global
health in patients with a variety of chronic conditions
(Table 1). The items measure self-rated health, quality of
life, physical functioning, psychological functioning, (satis-
faction with) social roles and activities, fatigue, and pain
[27]. All items are administered and scored on a 1-5 nom-
inal scale, with the exception of the pain item that is admin-
istered on a 0-10 numeric rating scale and rescored to a 1-5
scale. Four items (two physical functioning, one fatigue,and one pain) are used to compute the PROMIS-GH-10
PCS score and four other items (two psychological func-
tioning, one social satisfaction, and one quality of life) to
compute the MCS score [27]; both scales are estimated us-
ing item response theory parameters. They are expressed as
T-scores with a mean of 50 and standard deviation of 10,
with higher scores indicating better health [36].
2.2. Literature search
2.2.1. Data sources and searches
MEDLINE (via PubMed), EMBASE (Embase.com), CI-
NAHL (EBSCOhost), PsycINFO (EBSCOhost), and Sport-
Discus (EBSCOhost) were last searched on July 25, 2017.
The search strategy consisted of three groups of search
terms combined with the Boolean operator ‘AND’: (1) in-
strument names, (2) LBP, and (3) measurement properties.
A previously developed search filter retrieved studies on the
measurement properties in PubMed [22]; the same filter
was adapted for all the other databases (Appendix 1). No
restrictions for language or time were applied. Google
Scholar was also searched (last on July 28, 2017) with
the full names of the instruments, and the first 100 hits
for each instrument were screened for inclusion. Citation
tracking of the eligible studies was carried out in Web of
Science and by hand searching reference lists.
2.2.2. Study selection
To select studies, COSMIN definitions for nine measure-
ment properties were used [21]. Any report (e.g., book, on-
line article) presenting the instrument development was
included for the assessment of content validity [25]. Full-
text of studies asking patients 18 years with nonspecific
LBP [37] or professionals (e.g., researchers, clinicians) to
assess relevance, comprehensiveness, and/or comprehensi-
bility of an instrument were included as original content
validity studies [25]. Studies that aimed to evaluate one
of more of the other measurement properties were included
if full-text articles presented the results for adult patients
with nonspecific LBP. Studies that included patients with
a mix of pathologies were included if at least 75% of the
total sample had nonspecific LBP [38]. Studies that used
the instruments only as outcome measurements, or for vali-
dation of other instruments, were excluded [24].
Inclusion criteria were applied by two reviewers (A.C.
and S.J.K.) independently to titles and abstracts retrieved
with the searches. Potentially eligible full-texts were also
screened independently by two reviewers (A.C. and
R.W.O.). Consensus on inclusion was sought between re-
viewers in a face-to-face meeting and, in case of disagree-
ment, a third reviewer (C.B.T.) arbitrated.
2.3. Evaluation of the measurement properties
As per COSMIN guidance, measurement properties
were assessed in the following order: (1) content validity,
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Abbreviations: EQ-5D-5L, 5-level 5-item EuroQol; EQ-5D-3L, 3-level 5-item EuroQol; NHP, Nottingham health profile; PROM, patient-reported
outcome measure; PROMIS-GH-10, 10-item global health short form of the patient-reported outcomes measurement information system; SF36,
short form 36; SF12, 12-item short form.
a Each of these health concepts had a separate definition that is not presented here because the scope of this review was to assess the SF36 as
a measure of the construct HRQoL.
27A. Chiarotto et al. / Journal of Clinical Epidemiology 102 (2018) 23e37(2) internal structure (i.e., structural validity, internal con-
sistency, and cross-cultural validity), (3) the remaining
properties (i.e., testeretest reliability, measurement error,
criterion validity, construct validity, responsiveness) [24].
2.3.1. Risk of bias assessment and data extraction
To assess content validity, the instrument development
and original content validity studies should be evaluated
[25]. The quality of these two different type of studies were
assessed using newly developed standards (COSMIN risk of
bias checklist) [23,25]. Each standard is rated on a four-point
rating scale as ‘‘very good,’’ ‘‘adequate,’’ ‘‘doubtful,’’ or
‘‘inadequate’’. Total scores were determined for two parts
of the development study (concept elicitation and cognitive
interview) separately. Furthermore, each aspect of a content
validity study (i.e., relevance, comprehensiveness, compre-
hensibility) was evaluated separately. A total score is ob-
tained for each part by taking the lowest rating among the
standards (i.e., worst-score counts) [39]. More detailed infor-
mation on these new standards for content validity can be
found elsewhere [25]. Two reviewers (A.C. and C.B.T.) as-
sessed studies examining this measurement property sepa-
rately and reached consensus in a face-to-face meeting.
The risk of bias of the studies on the other measurement
properties was also assessed with the COSMIN risk of bias
checklist [23]. The four-point rating scale and worst-score
counts method are the same for every measurement prop-
erty, and a total score is provided for studies of eachmeasurement property in each study. Two reviewers (A.C.
and R.W.O.) assessed the risk of bias independently and
reached consensus in a face-to-face meeting.
For every study, data on patients’ characteristics and re-
sults were extracted by one reviewer (A.C.), and a random
25% of the extracted information, stratified per instrument,
was double checked by a second reviewer (R.W.O.).
2.3.2. Evidence synthesis
For content validity, the results of each study were rated by
two reviewers (A.C. and C.B.T.) independently against 10 es-
tablishedcriteria: fiveon relevance, oneoncomprehensiveness,
and four on comprehensibility [25]. Each criterion could be
rated as sufficient (þ), insufficient (), or indeterminate (?).
The same criteria were also scored based on the content of
the instrument itself, and reviewers found consensus in a
face-to-face meeting [25]. Subsequently, the results of all
studies on a specific instrument and the reviewer’s rating were
summarized qualitatively. An overall sufficient (þ), insuffi-
cient (), or inconsistent (6) ratingwasprovided for relevance,
comprehensiveness, and comprehensibility of each instrument.
For the other measurement properties, the results were
rated according to the consensus-based criteria proposed
by Prinsen et al. [7]. A priori hypotheses were formulated
by the review team to evaluate the results of studies on
construct validity and responsiveness, based on the results
of a previous systematic review on instruments for LBP
[40]. For both properties, correlations were expected to be:
28 A. Chiarotto et al. / Journal of Clinical Epidemiology 102 (2018) 23e37  0.60 with instruments measuring the same
construct (e.g., physical component summary [PCS]
or physical functioning subscale with a physical func-
tioning instrument or subscale);
 ! 0.60 and 0.30 with instruments measuring
largely related but dissimilar constructs (e.g., PCS
or physical functioning subscale with a pain instru-
ment or subscale);
 ! 0.50 and 0.20 with instruments measuring
moderately related but dissimilar constructs (e.g.,
PCS or physical functioning subscale with a mental
health instrument or subscale);
 ! 0.30 with instruments measuring weakly related or
unrelated constructs (e.g., PCS of physical func-
tioning subscale with a general health instrument or
subscale).
Two additional hypotheses were formulated for
responsiveness:
 The area under the curve to discriminate between
improved and unchanged patients (as defined in each
study) had to be 0.70;
 Effect size and standardized response means for
improved patients (as defined in each study) had to
be at least 0.50 larger than those for unchanged pa-
tients [41].
Within studies, construct validity and responsiveness
were considered sufficient (þ) if 75% of the hypotheses
were met, or insufficient () if 75% of the hypotheses
were not met, otherwise they were considered inconsistent
(6) [7]. Between studies, results were considered inconsis-
tent if they did not display the same results (i.e., all suffi-
cient, insufficient or inconsistent findings).
Thequality of evidence for eachmeasurement propertywas
rated according to the Grading of Recommendations, Assess-
ment, Development, and Evaluation (GRADE) approach [42]
adapted for this type of review into: ‘‘high,’’ ‘‘moderate,’’
‘‘low,’’ or ‘‘very low’’ [24,25]. For content validity, the evi-
dence quality could be downgraded because of risk of bias,
inconsistencyof results and indirectness, as outlinedelsewhere
[25]. For the othermeasurement properties, risk of bias, impre-
cision, inconsistency, and indirectnesswere taken into account
[24]. Quality of evidence was downgraded as follows:
 Risk of bias: one level if there was only one
‘‘adequate’’ study, two levels if there was only one
or more ‘‘doubtful’’ studies, and three levels if there
was only one or more ‘‘inadequate’’ studies;
 Imprecision: one level if the total patient sample was
!100 and 50, two levels if !50;
 Inconsistency: one level if the studies displayed
inconsistent findings (e.g., one study sufficient,
another study insufficient results);
 Indirectness: one level if a study did not specifically
address the construct (HRQoL) and/or the target pop-
ulation (adult patients with nonspecific LBP) [43].3. Results
From 4,809 records identified in the electronic searches,
95 full-text articles were retrieved, and 26 finally deemed
eligible; a further nine eligible studies were identified by
citation tracking; therefore, 35 studies were included
(Fig. 1). Sixty-nine full-texts were excluded: 14 did not
include patients with LBP, 13 did not assess a measurement
property as defined by COSMIN, 11 did not present results
separately for patients with nonspecific LBP, 10 included
patients with specific LBP, seven focused on measurement
properties of other instruments, five were unclear if they
included patients with nonspecific LBP, five analyzed only
a part of the eligible instruments (e.g., physical functioning
subscale of the SF-36), two were not relevant for this re-
view, one was a review, and one assessed an instrument that
was not self-reported but administered by an interviewer.
Seventeen of the included articles presented information
on the development of the instruments (Table 1). Among
the other 18 included studies, three evaluated the SF-36
and the EQ-5D-3L simultaneously [44e46], six only the
SF-36 [47e52], three only the SF-12 [53e55], and four only
the EQ-5D-3L [56e59]. The characteristics of these studies
and of the patients included are displayed in Table 2.
3.1. Short Form 36
Two books and three articles [32,60e63] reported infor-
mation on the SF-36 development (Table 1). The other nine
articles assessed structural validity, internal consistency,
testeretest reliability, construct validity, and/or responsive-
ness (Table 2). Eight studies reported on the SF-36 subscale
scores, three studies on PCS and MCS scores, and one eval-
uated the total score (Table 2).
3.1.1. Content validity
TheSF-36 developmentwas considered of inadequate qual-
ity because no patients were involved, and no cognitive inter-
view study was performed (Table 1). Because no additional
content validity studies were found, solely the reviewers’ rat-
ings counted for the evidence synthesis, leading to very low
quality evidence of sufficient content validity (Table 3).
3.1.2. Internal structure
Zwingmann et al. [52] assessed SF-36 structural validity
in a study of doubtful quality. Principal component analysis
with varimax rotation and confirmatory factor analysis were
applied at the subscale level. Component analysis extracted
two factors with eigenvalues equal to 2.3 and 2.8, respec-
tively (total explained variance 63%). Three subscales (phys-
ical functioning, role physical, and bodily pain) loaded
O0.70 on the PCS, the other five O0.50 on the MCS.
Confirmatory analysis found the same subscales loading on
the same components (Goodness-of-Fit index 5 0.96,
adjusted Goodness-of-Fit index 5 0.91), with the exception


















Other measurement properes 18 
Citaon tracking 9
Fig. 1. Flow chart of results of search strategy and selection of records.
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is supposed to load on the MCS, these results on the unidi-
mensionality of the two component scores were considered
inconsistent based on low quality evidence.
Two studies [48,52] of very good quality assessed the inter-
nal consistency of the subscales, finding a Cronbach’s alpha
O0.70 for seven of eight subscales in each study. According
to recent COSMIN guidance [24], because no studies assessed
the unidimensionality of the SF-36 subscales, these results
cannot provide evidence in support of this measurement prop-
erty. One study [47] evaluated internal consistency of the total
scale in a study of inadequate quality (Cronbach’s
alpha5 0.80). No studies assessed cross-cultural validity.3.1.3. Other measurement properties
In one study of doubtful quality (Table 4), sufficient
testeretest reliability was found for the subscales (low
quality evidence). No studies assessed testeretest reliability
of PCS, MCS, and total score; likewise, measurement error
was not evaluated.
Construct validity was evaluated for subscales, PCS,
MCS, and total scores (Appendix 2). Low quality evidence(due to risk of bias and inconsistent results across studies)
of inconsistent construct validity was found for the subscales
(Table 3). High quality evidence of insufficient construct val-
idity was found for both PCS and MCS scores (Table 3). For
the total score, there was low quality evidence (due to risk of
bias) of sufficient construct validity (Table 3).
Responsiveness was also evaluated for subscales, PCS,
MCS, and total scores (Appendix 3). For the subscales, hy-
potheses could not be tested in three studies [50e52] because
only overall effect sizes were reported; in the study by Suarez-
Almazor et al. [46], inconsistent results were found (very low
quality evidence due to riskofbias and imprecision) as11of32
hypotheses were met (34%) (Table 3). Low quality evidence
(due to risk of bias and inconsistency) of inconsistent respon-
siveness was found for PCS and MCS scores (Table 3). Suffi-
cient responsiveness was found for the SF-36 total score (low
quality evidence,Table3), basedonone study [47]with anarea
under the curveO0.70.
3.2. Short Form 12
One study [33] reported information on the SF-12 devel-
opment; three studies [53e55] assessed the following
Table 2. Characteristics of the studies assessing the measurement properties of HRQoL instruments in patients with low back pain
PROM(s) Reference Language (country) Study design Health intervention(s) LBP specifics
SF-36; EQ-5D-3L Suarez-Almazor 2000 [46] English (Canada) Longitudinal O3 mo





SF-36; EQ-5D-3L Eker 2007 [45] Turkish Cross-sectional O3 mo
SF-36 Bullinger 1995 [48] German (Germany) Longitudinal




SF 36 Zwingmann 1998 [52] German (Germany) Cross-sectional Inpatient
rehabilitation




defined) 6 leg pain
SF-36 Dunn 2003 [49] English (UK) Longitudinal
SF-36 Weigl 2006 [51] German (Germany) Longitudinal Individual health
resort programs
SF-12 Luo 2003 [54] English (US) Longitudinal
SF-12 Turner 2003 [55] English (US) Longitudinal Work-related claim
SF-12 Diaz-Arribas 2017 [53] Spanish (Spain) Longitudinal Conservative
management
14 d





O4 wk and !6 mo
EQ-5D-3L Mueller 2013 [57] English (US) Cross-sectional




EQ-5D-3L Whynes 2013 [59] English (UK) RCT Epidural steroid
injections
6 leg pain
Abbreviations: EQ-5D-3L, 3-level EuroQol 5D; n, sample size; NSAIDs, non-steroidal anti-inflammatory drugs; PROM(s), patient-reported
outcome measure(s); RCT, randomized controlled trial; SD, standard deviation; SF-12, short form 12 health survey; SF-36, short form 36
health survey; VAS, visual analogue scale; m, mean.
Empty cells indicate not assessed items.
a Measurement error was assessed in 163 patients, responsiveness in 359, but characteristics of these patients alone were not presented.
30 A. Chiarotto et al. / Journal of Clinical Epidemiology 102 (2018) 23e37measurement properties: internal consistency, measurement
error, construct validity, and responsiveness (Table 2). Each
study evaluated SF-12 PCS and MCS scores.3.2.1. Content validity
The SF-12 was derived from the SF-36 using regression
methods [33]; its development was considered inadequate
as no patients were involved, and no cognitive interviewstudy was performed (Table 1). No additional content val-
idity studies were retrieved. There was very low quality ev-
idence of sufficient content validity (based on the
reviewers’ ratings only) (Table 3).3.2.2. Internal structure
No studies evaluated the SF-12 structural and cross-
cultural validity. The only study [54] assessing internal
Measurement properties Scores used
Patient characteristics
n Female (%) Age (m ± SD, years) Pain duration (m ± SD, years) Working (%)
Responsiveness Subscales and component
summaries (SF-36). Utility
and VAS (EQ-5D)
46 65 50 6 15 10 6 11
Responsiveness Component summaries
(SF-36). Utility (EQ-5D)
250 44 40 6 9 8 6 7 44
Construct validity Subscales (SF-36). Domains
(EQ-5D)
















Total (all properties) and
subscales (construct
validity)
132 51 42 6 9 2 (median) 92 (full-time)
Testeretest reliability Subscales 14 57 45 6 8
Construct validity,
responsiveness




Component summaries 2520 55 52 6 16 31
Construct validity,
responsiveness
Component summaries 309 37 41 6 11 76
Measurement error,
responsiveness




Construct validity Utility, VAS and domains 8,385 60 53 6 16
Construct validity,
responsiveness
Utility and VAS 151 55 52 6 16 47
Responsiveness Utility and VAS 39
31A. Chiarotto et al. / Journal of Clinical Epidemiology 102 (2018) 23e37consistency was of very good quality and found Cronbach’s
alpha equal to 0.77 and 0.80 for PCS and MCS scores,
respectively. This study does not represent evidence on this
measurement property because the unidimensionality of
these scores was not assessed in any study [24].
3.2.3. Other measurement properties
No studies assessed SF-12 testeretest reliability. Diaz-
Arribas et al. [53] (doubtful quality) was the only studyassessing measurement error. The MIC values presented
in this study were larger than the smallest detectable change
values (Table 4), providing low quality evidence for suffi-
cient measurement error for both PCS and MCS.
Moderate quality evidence (downgraded for risk of bias)
(Appendix 2) of sufficient construct validity was found for
PCS, although low quality evidence (risk of bias and incon-
sistent results) of inconsistent construct validity for MCS
(Table 3). Very low quality evidence (due to risk of bias
Table 3. Evidence synthesis on measurement properties of HRQoL instruments in patients with low back pain
Measurement properties
SF-36 SF-12 EQ-5D-3L EQ-5D-5L NHP
PROMIS-
GH-10
Subscales PCS MCS TOT PCS MCS Utility VAS Domains Utility VAS Domain Subscales PCS MCS
Content validity
Relevance
Rating þ þ þ þ þ
Quality All: very low
Comprehensiveness
Rating þ   þ þ
Quality All: very low
Comprehensibility
Rating þ þ þ þ þ
Quality All: very low
Construct validity
Rating 6   þ þ 6   6 þ
Quality Low High High Low Modera-te Low High High Low Low
Responsiveness
Rating 6 6 6 þ 6  6 6
Quality Very low Low Low Low Very low Low Moderate Low
Abbreviations: EQ-5D-3L, 3-level EuroQoL 5D; EQ-5D-5L, 5-level EuroQoL 5D; MCS, mental component summary; NHP, Nottingham health
profile; PCS, physical component summary; PROMIS-GH-10, 10-item PROMIS global health short form; SF-36, short form 36; SF-12, short form
12; VAS, visual analogue scale; ‘‘þ’’, sufficient results; ‘‘‒’’, insufficient results; ‘‘6’’, conflicting results.
Empty cells represent measurement properties not assessed in any study.
The following measurement properties were assessed only for one instrument, and their evidence synthesis is not reported in the table: struc-
tural validity of SF-36 PCS and MCS was inconsistent (low quality evidence), testeretest reliability of SF-36 subscales was sufficient (low quality
evidence), measurement error of SF-12 PCS and MCS was sufficient (low quality evidence). Internal consistency was assessed for the SF-36 sub-
scales, SF-36 TOT, and for SF-12 PCS, and MCS; the results of these studies are presented in the text, but they do not represent for this mea-
surement property, as the unidimensionality of the assessed tools has not been tested in patients with low back pain. Cross-cultural validity
was not assessed for any instrument.
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of the PCS, although low quality evidence (because of risk
of bias) was present for insufficient responsiveness of the
MCS (Table 3).
3.3. 3-Level EuroQoL 5D
Two studies reported information on the EQ-5D-3L devel-
opment [29,34]; other seven articles [44e46,56e59] assessed
its measurement properties, six focusing on the utility score,
four on the VAS, and two on the domain scores (Table 2).
3.3.1. Content validity
The EQ-5D-3L development was rated inadequate
because no patients were involved in the instrument
development, no clear definition of the construct to be
measured was provided, and no cognitive interview study
was performed (Table 1). There was very low quality ev-
idence of sufficient relevance and comprehensibility and
very low quality evidence of insufficient comprehensive-
ness (Table 3).
3.3.2. Internal structure
No studies tested structural validity, internal consistency,
or cross-cultural validity in patients with LBP.3.3.3. Other measurement properties
Testeretest reliability and measurement error were not
assessed in any study. High quality evidence for insufficient
construct validity (Appendix 2) was found for utility and
VAS scores (Table 3). For the domain scores, low quality
evidence (due to risk of bias) was found for inconsistent re-
sults (Table 3) because two studies of doubtful quality re-
ported inconsistent results [45,57].
There was moderate quality evidence for inconsistent
responsiveness of the utility score (Table 3), as results were
largely inconsistent across studies (Appendix 3). Low qual-
ity evidence (because of risk of bias and inconsistency) was
found for inconsistent responsiveness of the VAS score
(Table 3). No studies assessed the responsiveness of the
domain scores.
3.4. 5-Level EuroQol 5D
One article reported information on the development of the
EQ-5D-5L [30] and was rated as inadequate because a clear
description of the construct to be measured was not provided
as it referred to the development of the EQ-5D-3L (Table 1).
A pilot study (focus groups) was conducted to assess the
comprehensibility (but not comprehensiveness) of the instru-
ment; that study was rated as doubtful quality because it was
Table 4. Testeretest reliability and measurement error of HRQoL instruments in patients with low back pain
PROM Reference n Study quality Time interval Scores used
Testeretest reliability
ICC (lower limit, 95% CI)
SF-36 Dunn 2003 [49] 14 Doubtful 2 wk Subscale:
Physical functioning 0.93 (0.84)
Role physical 0.81 (0.51)
Role emotional 0.74 (0.43)
Social functioning 0.88 (0.71)
Mental health 0.90 (0.76)
Vitality 0.94 (0.85)
Bodily pain 0.89 (0.63)
General health 0.96 (0.90)
Measurement error
SDC (% scale range)
SF-12 Diaz-Arribas 2017 [53] 163 Doubtful 12 mo Component summary:
Physical 0.56 (1)a
Mental 3.77 (6)a
Abbreviations: 95% CI, 95% confidence interval; ICC, intraclass correlation coefficient; n, number; PROM, patient-reported outcome measure;
SDC, smallest detectable change.
a Unclear that SDC formula was used.
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sors. The reviewers rated the EQ-5D-5L content validity for
patients with LBP as sufficient for relevance and comprehen-
sibility (very low quality evidence), and as insufficient for
comprehensiveness (very low quality) (Table 3).
No studies assessed the measurement properties of this
instrument in patients with LBP.3.5. Nottingham Health Profile
Three studies reported the development of the NHP
[35,64,65], which was rated as inadequate because patients
were not involved in the concept elicitation study (Table 1).
No studies assessed the content validity. There was very
low quality evidence for sufficient content validity, as rated
by the reviewers (Table 3).
No studies were found on the internal structure, reli-
ability, and/or responsiveness of the NHP in patients with
LBP. One study [48] assessed the construct validity of its
subscales as compared to the SF-36 subscales, providing
low quality evidence (due to risk of bias, Table 3) of suffi-
cient construct validity as 37 of 48 hypotheses were met
(77%, Appendix 2).3.6. PROMIS global health short form
Four articles and one report included information on
the PROMIS-GH-10 development [27,66e69]. Develop-
ment was rated inadequate because, despite patients’
involvement in developing PROMIS items [69], they
were not specifically involved in selecting the most rele-
vant (sub)domains to be included in this instrument(Table 1). There was very low quality evidence of suffi-
cient content validity based solely on the reviewers’ rat-
ings (Table 3). No studies assessing the measurement
properties of the PROMIS-GH-10 in patients with LBP
were retrieved.4. Discussion
This systematic review highlights the scarcity of high
quality evidence on the measurement properties of SF-36,
SF-12, EQ-5D-3L, EQ-5D-5L, NHP, and PROMIS-GH-10
in patients with LBP. Foremost, there is very low quality
evidence for the content validity of these six instruments
in patients with LBP (Table 3). There was high quality ev-
idence only of insufficient construct validity of SF-36 phys-
ical and mental summary scores, and EQ-5D-3L utility and
VAS scores. Construct validity and responsiveness were the
most often assessed properties, mainly for SF-36, SF-12,
and EQ-5D-3L. Moderate quality evidence was found for
SF-12 PCS score inconsistent construct validity and EQ-
5D utility score inconsistent responsiveness (Table 3). All
other properties of any instrument were underpinned by
lower quality evidence or not assessed.
Content validity is considered by clinimetric and psy-
chometric experts as the first measurement property to
consider when selecting an instrument [7,25]. The six in-
struments assessed in this review were developed without
patient input (Table 1). For this reason, content validity
of these instruments should be urgently assessed in patients
with LBP. The HRQoL definition used in a recent
consensus exercise on core outcome domains for LBP
34 A. Chiarotto et al. / Journal of Clinical Epidemiology 102 (2018) 23e37may be adopted as a starting point [5]. This definition high-
lights three major subdomains (i.e., physical, mental, and
social) but does not provide much detail on what should
be included within each subdomain. It should be recog-
nized that there is no consensus on the definition of HRQoL
and that other definitions exist [70e72]. Patients have indi-
cated that an acceptable level of HRQoL is required for re-
covery from an LBP episode [4], but we did not explore
what HRQoL really means for them. This issue also needs
to be addressed.
The structural validity (second measurement property
to consider when selecting an instrument [7]) of HRQoL
instruments in patients with LBP has not been sufficiently
investigated for the SF-36 (Table 3). The EQ-5D instru-
ments provide two ‘‘unidimensional’’ HRQoL scores
(utility index and VAS), the other instruments provide
component summary and/or subscale scores. It is unclear
which performs best in patients with LBP. HRQoL defini-
tions usually highlight the multidimensional nature of the
domain, but it remains unclear if HRQoL can be
adequately expressed using the total score of a multidi-
mensional instrument or only by the subscales scores.
Head-to-head comparison of available instruments is
required, and various psychometric methods, such as
(exploratory and confirmatory) factor analysis, bifactor
analysis, Mokken scale analysis, or parametric item
response theory, are available to address this issue [7].
An alternative may be to consider the total scores of these
instruments as formative models, and this would not
require assessment of structural validity. However, to
consider these instruments as based on formative HRQoL
models, there should be high quality evidence on their
sufficient content validity. Scores from the same HRQoL
instruments have been pooled in systematic reviews on in-
terventions [38,73], under the assumption that validity is
the same across cultures, countries and languages; howev-
er, because there are no studies on the cross-cultural val-
idity of these instruments (Table 3), differential item
functioning should be tested to see if this cross-cultural
equivalence assumption holds [74].
The most important finding regarding the other measure-
ment properties assessed in this review is the insufficient
construct validity of the SF-36 PCS and MCS scores and
of the EQ-5D-3L utility and VAS scores. Based on these re-
sults, it is essential to better assess the construct validity of
SF-36 subscales as these may display better results than
summary scores. Regarding the EQ-5D, it should be under-
lined that only the EQ-5D-3L version has been assessed in
patients with LBP and not the EQ-5D-5L [30]. This newer
version has shown improved validity in other populations
[75]. Some researchers do not consider the EQ-5D utility
score a patient-reported outcome measure of HRQoL [26]
because it is not based on direct patient-reporting, but
rather on values derived from the general population.
Others disagree, equating the valuation of EQ-5D profiles
to the use of norm scores, as applied in PROMIS-GH-10.This review included six instruments among those most
frequently used or recommended for HRQoL [8e13,28];
however, other instruments should also be included in
future head-to-head comparisons in patients with LBP. Ba-
graith et al. [76,77] have recently developed the LBP Core
Set Self-Report Checklist that was based on the categories
included in the ICF core set for LBP [78]. This unidimen-
sional tool includes both activity limitations and participa-
tion restrictions, it could be considered as an HRQoL
instrument and compared to the others included in this re-
view. The same argument holds for another recently devel-
oped tool, the Musculoskeletal Health Questionnaire [79],
which aims at including all domains relevant to patients
with musculoskeletal complaints.
The results of this systematic review informed an inter-
national and multidisciplinary Delphi process to endorse
core instruments for LBP clinical trials; however, none of
the HRQoL instruments met the prespecified 67% cutoff
for consensus (although the SF-12 came close) [26]. To
improve measurement standardization, the international
consortium overseeing the core set initiative for LBP
decided to recommend the SF-12 and the PROMIS-GH-
10 for HRQoL, as they both provide PCS and MCS scores,
and the PROMIS-GH-10 represents a free of charge option
[26]. On the other hand, the SF-36 was not endorsed
because it was considered too long for inclusion in every
clinical trial, and the EQ-5D because it provided scores that
cannot be pooled with the other instruments’ scores (i.e.,
SF12 and PROMIS-GH-10) [26]. However, these recom-
mendations are provisional, and taken together with the re-
sults of this review, reinforce the message that substantial
input is needed from the scientific community to generate
more evidence on HRQoL measurement in LBP.
This study was conducted according to current guidance
on systematic reviews of patient-reported outcome mea-
sures [7,21,23e25]. However, the reviewed instruments
were developed before the more recent developments in
clinimetrics and psychometrics. Specifically, they could
not consult the COSMIN risk of bias checklist [23] in the
design phase of the study. Additionally, given that the
EQ-5D-5L and PROMIS-GH-10 were developed 10 to
20 years later than the other instruments, it is no surprise
that studies in patients with LBP are lacking. This is a
reason why there are less studies assessing the measure-
ment properties of these instruments. We reiterate that these
newer instruments should be assessed in head-to-head com-
parisons in patients with LBP.
The HRQoL instruments assessed in this review have
been assessed in several other populations [14], but, up
to now, there is no evidence showing whether it is appro-
priate to translate findings on measurement properties
from generic populations to populations with specific
health conditions and between health conditions. In this
review, we focused on their measurement properties in pa-
tients with LBP following the approach routinely used for
systematic reviews of clinical trials, observational and
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tential limitation is that the evidence syntheses were per-
formed lumping together studies from different cultures,
countries, and languages. The same approach is routinely
used in systematic reviews of clinical trials and observa-
tional studies in patients with back pain disorders
[38,73,80,82e86]; splitting the results of these studies
may be considered equally contentious as there is no evi-
dence clearly indicating the best way to synthesize evi-
dence on instrument measurement properties.
Meanwhile, for more detailed scrutiny, we provided qual-
ity and results of each study specifying language and
country (Tables 2 and 4, Appendix 2 and 3). Another po-
tential limitation of this review is that the search strategy
was designed to identify studies on patients with LBP
(Appendix 1), without specifically targeting the develop-
ment studies of the instruments that were conducted in
generic populations; nevertheless, eight articles on the in-
struments development were found with the initial search
and the remaining nine through citation tracking
(Figure 1).
Evidence related to the measurement properties of
HRQoL instruments in patients with LBP is inconclusive
(Table 3). With a few exceptions, higher quality evidence
is needed on all measurement properties of the instruments
included in this review and other instruments. Head-to-head
comparisons of the content validity of the various instru-
ments should have priority.Acknowledgments
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